Search
Showing results for "rishi kotecha"
Present a valuable resource for drug discovery and have identified ROM as a promising therapeutic for MLL-rearranged iALL
The main aim of our Leukaemia Translational Research Team is to test innovative therapeutic approaches, with a focus on clinical translation of this knowledge, to improve the outcomes of children suffering from leukaemia.
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required.
The Australian arm of an international clinical trial looking at improved treatments for young babies with leukaemia has been awarded funding from the MRFF.
A pilot clinical study has found an immunotherapy drug can dramatically increase survival rates for babies with a rare form of leukaemia, paving the way for a major international clinical trial.
Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.
Associate Professor Rishi Kotecha, Co-Head of Leukaemia Translational Research at The Kids Research Institute Australia Cancer Centre and Consultant Paediatric Oncologist at Perth Children's Hospital, has been named Cancer Council WA’s 2024 Cancer Researcher of the Year.
Despite initial improvements in survival of infants with ALL since establishment of the first pediatric cooperative group ALL trials, the poor outcome has...
Paediatric cancer is the leading cause of disease-related death in Australian children. Limited research focuses on cancer in Aboriginal and Torres Strait Islander children. Although there appears to be a lower incidence of cancer overall in Aboriginal and Torres Strait Islander children compared with non-Indigenous children, a high proportion of Aboriginal and Torres Strait Islander children are diagnosed with acute myeloid leukaemia.
A pilot clinical study, led in Australia by a The Kids Research Institute Australia and Perth Children's Hospital researcher, has found an immunotherapy drug can dramatically increase survival rates for babies with a rare form of leukaemia, paving the way for a major international clinical trial.